BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Myelofibrosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Myelofibrosis\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06770842-9910@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 2 readout est. (NCT0677084
 2)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 2\, Myelofibrosis.\nS
 tudy: Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis\nEstimate
 d primary completion: December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06770842
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345495-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06345495)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: High Do
 se Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis P
 atients With Splenomegaly\nEstimated primary completion: 1 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0634549
 5
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03069326-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT03069326)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Clini
 cal Study to Test the Effects of Ruxolitinib And Thalidomide Combination f
 or Patients With Myelofibrosis\nEstimated primary completion: February 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT030
 69326
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176198-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT04176198)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis\nEstimated 
 primary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04176198
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05320198-928@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Selcodebart: Phase 1/2 readout est. (NCT05320198)
DESCRIPTION:Selcodebart\, phase 1/2\, Anemia of Myelofibrosis.\nStudy: Stud
 y of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodyspl
 astic Syndrome and Anemia\nEstimated primary completion: May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/selcodebart#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05320198
URL:https://assetmemo.bio/drug/selcodebart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-2266@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Selinexor: Phase 2 readout est. (NCT05980806)
DESCRIPTION:Selinexor\, phase 2\, Myelofibrosis.\nStudy: A Study of Selinex
 or Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Mod
 erate Thrombocytopenia\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/selinexor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05980806
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05980806)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Study
  of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibro
 sis and Moderate Thrombocytopenia\nEstimated primary completion: June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0598
 0806
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909136-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06909136)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy to Evaluate Safety \, Efficacy and Pharmacokinetics of WJ01024 Tablets 
 Combined With Ruxolitinib in Patients With Myelofibrosis\nEstimated primar
 y completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06909136
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04282187-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT04282187)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: Decitab
 ine With Ruxolitinib\, Fedratinib or Pacritinib for the Treatment of Accel
 erated/Blast Phase Myeloproliferative Neoplasms\nEstimated primary complet
 ion: 11 November 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ruxolitinib-jakafi#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04282187
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06468033-9910@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Ropeginterferon alfa-2b (Besremi): Phase 3 readout est. (NCT0646803
 3)
DESCRIPTION:Ropeginterferon alfa-2b (Besremi)\, phase 3\, Myelofibrosis.\nS
 tudy: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Int
 ermediate-1 Risk\nEstimated primary completion: 18 November 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besre
 mi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6468033
URL:https://assetmemo.bio/drug/ropeginterferon-alfa-2b-besremi#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773195-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06773195)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy of Ruxolitinib in Combination With Ulixertinib in People With Myelofibr
 osis\nEstimated primary completion: January 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06773195
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05037760-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT05037760)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Study
  of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofib
 rosis\nEstimated primary completion: 28 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05037760
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859424-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT06859424)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: A Platf
 orm Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-V
 ersus-Host Disease Prophylaxis in Patients With Hematologic Malignancies U
 ndergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplant
 ation\nEstimated primary completion: June 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06859424
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04817007-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT04817007)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: A Stu
 dy to Assess the Safety and Tolerability of BMS-986158 Alone and in Combin
 ation With Either Ruxolitinib or Fedratinib in Participants With Blood Can
 cer (Myelofibrosis)\nEstimated primary completion: 31 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04817007
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883382-1402@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281028
DTEND;VALUE=DATE:20281029
SUMMARY:Zepuping (jaktinib): Phase 1/2 readout est. (NCT07883382)
DESCRIPTION:Zepuping (jaktinib)\, phase 1/2\, Myelofibrosis.\nStudy: An Exp
 loratory Study on the Use of Gecacitinib in Patients With Myeloid Malignan
 cies and Myelofibrosis During the Peri-transplant Period Following Allogen
 eic Hematopoietic Stem Cell Transplantation\nEstimated primary completion:
  28 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jak
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07883382
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938580-1402@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zepuping (jaktinib): Phase 2 readout est. (NCT07938580)
DESCRIPTION:Zepuping (jaktinib)\, phase 2\, Myelofibrosis.\nStudy: Gecaciti
 nib Plus Luspatercept in Patients With Myelofibrosis and Anemia\nEstimated
  primary completion: December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/jaktinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07938580
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734077-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07734077)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Revum
 enib in Patients With Myelofibrosis\nEstimated primary completion: 1 Decem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib
 -jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07734077
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471503-1402@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Zepuping (jaktinib): Phase 2 readout est. (NCT07471503)
DESCRIPTION:Zepuping (jaktinib)\, phase 2\, Myelofibrosis.\nStudy: Gecaciti
 nib Pre-\, During- and Post-HSCT for Patients With Primary or Secondary My
 elofibrosis\nEstimated primary completion: 1 April 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/jaktinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07471503
URL:https://assetmemo.bio/drug/jaktinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06327100-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT06327100)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Open 
 Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosi
 s (PMF)\, Post-Polycythemia Vera Myelofibrosis (Post-PV MF)\, or Post-Esse
 ntial Thrombocytosis Myelofibrosis (Post-ET MF)\nEstimated primary complet
 ion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxo
 litinib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06327100
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07447817-2266@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20300524
DTEND;VALUE=DATE:20300525
SUMMARY:Selinexor: Phase 2 readout est. (NCT07447817)
DESCRIPTION:Selinexor\, phase 2\, Myelofibrosis.\nStudy: Selinexor and Pacr
 itinib in JAK Inhibitor-naïve MF Patients With Cytopenias\nEstimated prim
 ary completion: 24 May 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/selinexor#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07447817
URL:https://assetmemo.bio/drug/selinexor#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228624-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Ruxolitinib (Jakafi): Phase 2 readout est. (NCT07228624)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 2\, Myelofibrosis.\nStudy: Ruxolit
 inib Before\, During and After Hematopoietic Cell Transplant in Older Pati
 ents With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Ne
 oplasm Overlap Syndromes\nEstimated primary completion: 1 September 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ruxolitinib-jakafi#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072286
 24
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128381-7619@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Ruxolitinib (Jakafi): Phase 1/2 readout est. (NCT07128381)
DESCRIPTION:Ruxolitinib (Jakafi)\, phase 1/2\, Myelofibrosis.\nStudy: Phase
  I/II Clinical Trial of Axatilimab\, a CSF1R Monoclonal Antibody\, in Comb
 ination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) a
 nd Chronic Myelomonocytic Leukemia (CMML)\nEstimated primary completion: 3
 1 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruxoliti
 nib-jakafi#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07128381
URL:https://assetmemo.bio/drug/ruxolitinib-jakafi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
